CD274 and head and neck squamous cell carcinoma: Following the durable anti‐tumor activity and tolerable safety profile of pembrolizumab in heavily pre‐treated patients who suffer R/M HNSCC, it was approved for those with metastatic or recurrent disease that has progressed on platinum‐containing chemotherapy and for all PD‐L1 expression subgroups [59].